Retatrutide is a triple receptor agonist peptide under preclinical and clinical investigation, targeting GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors simultaneously. Published research has examined its binding kinetics and downstream intracellular signaling profiles at each receptor subtype in controlled in vitro systems. Studies have also characterized its pharmacokinetic parameters including receptor binding affinity ratios, subcutaneous half-life, and metabolic clearance pathways in animal model research contexts.
\n
Class: Triple GIP/GLP-1/Glucagon Receptor Agonist | Purity: ≥98% (HPLC) | Format: Lyophilized powder
\n
Storage: −20°C, desiccated, protected from light | Reconstitution: Bacteriostatic water recommended for research use
\n
\n
\n
⚠️ Research Use Only. This compound is intended exclusively for qualified in vitro and laboratory research. It is not approved for human consumption, is not a dietary supplement, and has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease or health condition. Researchers are solely responsible for compliance with all applicable federal, state, and local laws governing research chemical use.
